



Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi. We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

## **Cais Rhyddid Gwybodaeth / Freedom of Information request** **Ein Cyf / Our Ref: 23-D-011**

Please note that we have provided this information for the period January to March 2023.

### **You asked:**

**1. How many haemophilia A patients are registered with your centre, and how many of these patients are classified as exhibiting mild, moderate, or severe disease.**

87 patients, 52 mild, 14 moderate, 21 severe

**2. In the last three months, how many Haemophilia A patients, including on-demand patients, have been treated with the following products?**

- **Advate** - <5\* patients
- **Adynovi** – 0 patients
- **Elocta** – 0 patients
- **Esperoct** - <5\* patients
- **Factor Eight Inhibitor Bypass Activity (FEIBA)** - <5\* patients
- **Hemlibra (standalone)** – 0 patients
- **Hemlibra in combination with any Factor VIII**– 0 patients
- **NovoEight** – 0 patients
- **NovoSeven RT** – 0 patients
- **Obizur** – 0 patients
- **Refacto AF**– 0 patients
- **Any other products** – 0 patients

**3. For patients treated with Advate in the last three months, please provide:**

- **the number of haemophilia A patients treated prophylactically** – 0 patients
- **the number of haemophilia A patients treated for any other reason (e.g. surgery, on-demand, breakthrough bleeds)** <5\* patients for other reasons



**4. In the last three months, how many patients were treated with the following products for severe Haemophilia A ONLY?**

- **Advate** - <5\* patients
- **Adynovi** – 0 patients
- **Elocta** – 0 patients
- **Esperoct** – 0 patients
- **Factor Eight Inhibitor Bypass Activity (FEIBA)** – 0 patients
- **Hemlibra (standalone)** – 0 patients
- **Hemlibra in combination with any Factor VIII**– 0 patients
- **NovoEight** – 0 patients
- **NovoSeven RT** – 0 patients
- **Obizur** – 0 patients
- **Refacto AF** – 0 patients
- **Any other products**– 0 patients

\* Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

